Impact Investments in Cancer Care Innovation

We provide a full-suite hybrid VC & PE
funding to scale health care breakthroughs

Growth

Our Unique Perspective
on Investment

Hybrid Venture Capital-Private Equity: Direct
connections and active participation to deliver
impactful growth

About Us

Our Portfolio of Innovative Companies

We were part of these companies’ successful growth,

leading to a real change in today’s healthcare

20+ Clinics in Europe

Public Listed on NASDAQ

Experts in Integrative Medicine

Acquired in 2017

Public Listed on NYSE

Early-stage Investors

Latest News

Alpha Tau Receives FDA Approval to Expand U.S. REGAIN Trial of Alpha DaRT® for Recurrent Glioblastoma

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement expanding its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial.

הילד חולה הסרטן לא יכול לחכות: השאלה שכל מפלגה חייבת עליה תשובה

טור דעה מאת שימי גשייד, מנכ״ל רחשי לב, הקורא למפלגות בישראל להתחייב לתוכנית מעשית ומתוקצבת לחיזוק מערכת הבריאות ולשיפור התמיכה בילדים חולי סרטן ובמשפחותיהם

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT®

Japan’s MHLW has granted Shonin marketing approval for Alpha Tau’s Alpha DaRT intratumoral alpha-radiation device

Amethyst's HBI Oncology Community – a new platform driving cross-sector collaboration in cancer care.

Amethyst Healthcare Group is proud to launch a new dedicated Oncology Community with Healthcare Business International (HBI) designed to bring the industry leaders together and accelerate progress in oncology.

Alpha Tau to Participate at Jefferies Global Healthcare Conference

Alpha Tau Medical today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.